We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.34 | 0.69% | 49.43 | 49.43 | 49.44 | 49.885 | 49.40 | 49.57 | 2,508,118 | 20:29:26 |
From Apr 2019 to Apr 2024
By Colin Kellaher
German biotechnology company BioNTech AG on Friday said it will receive an equity investment of 80 million euros ($91 million) from Sanofi SA (SAN.FR, SNY) as it extends a 2015 research collaboration with the French drug maker.
BioNTech also said it has agreed with Sanofi to co-develop the first cancer immunotherapy candidate from the collaboration, which is entering clinical testing in multiple solid tumors.
BioNTech, which is developing individualized immunotherapies to treat cancer and prevent infectious diseases, in November 2015 announced the deal with Sanofi that included a $60 million upfront payment and potential further payments topping $300 million per product.
The Mainz, Germany, biotechnology company last year formed a multi-year collaboration with Pfizer Inc. (PFE) to develop messenger-RNA-based flu vaccines that included $120 million in upfront payments and up to $305 million in potential milestone payments.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2019 06:37 ET (11:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
